ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i6.2829ppharm-2553Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСовременные возможности и частные вопросы вакцинопрофилактики ротавирусной инфекцииModern Features and Particular Issues of Rotavirus Preventive Vaccinationhttps://orcid.org/0000-0003-0797-5612ФедосеенкоМ. В.FedoseenkoMarina V.

Федосеенко Марина Владиславовна, кандидат медицинских наук, заведующая отделом разработки научных подходов к иммунизации пациентов с отклонениями в состоянии здоровья и хроническими болезнями НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского» , доцент кафедры факультетской педиатрии Института материнства и детства ФГАОУ ВО РНИМУ им. Н.И. Пирогова

119333, Москва, ул. Фотиевой, д. 10, стр. 1

 

Marina V. Fedoseenko, MD, PhD

10, Fotievoy Str., building I, Moscow, 119333

titovamarina@mail.ruhttps://orcid.org/0000-0003-1453-4671КалюжнаяТ. А.KaiiuzhnaiaTatiana A.

Калюжная Татьяна Анатольевна, к.м.н. 

Москва

 

Tatiana А. Kaiiuzhnaia, MD, PhD

Moscow

kaliuzhnaiatatiana83@gmail.comhttps://orcid.org/0000-0002-3270-4374ШахтахтинскаяФ. ЧShakhtakhtinskayaFiruza Ch.

Шахтахтинская Фируза Чингизовна, к.м.н. 

Москва

Firuza Ch. Shakhtakhtinskaya, MD, PhD

Moscow

doc.firuza@gmail.comhttps://orcid.org/0000-0001-5808-1438ТолстоваС. В.TolstovaSvetiana V.

Толстова Светлана Васильевна 

Москва

Svetiana V. Tolstova, MD

Moscow

tolsto4eva@mail.ruСельвянА. М.SelivyanArevaiuis M.

Сельвян Аревалуис Месроповна 

Москва

Arevaiuis М. Seivyan, MD

Moscow

arev.92@mail.ruНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; РНИМУ им. Н.И. ПироговаРоссияResearch institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of SurgeryRussian Federation202409012025216516524Copyright © Федосеенко М.В., Калюжная Т.А., Шахтахтинская Ф.Ч., Толстова С.В., Сельвян А.М., 20242024Федосеенко М.В., Калюжная Т.А., Шахтахтинская Ф.Ч., Толстова С.В., Сельвян А.М.Fedoseenko M.V., Kaiiuzhnaia T.A., Shakhtakhtinskaya F.C., Tolstova S.V., Selivyan A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2553

Ротавирус признается одним из наиболее распространенных в мире возбудителей острого гастроэнтерита среди детей первых 5 лет жизни и оказывает существенное влияние на детскую заболеваемость и смертность. Рекомендованная ВОЗ к рутинному применению вакцинация младенцев против ротавирусной инфекции привела к значительному сокращению уровня заболеваемости, госпитализации и расходов, связанных с последствиями ротавирусной инфекции, в странах, достигших высокого охвата ротавирусными прививками. Однако следует знать о существовании ряда особенностей практического применения ротавирусных вакцин, от которых зависит их безопасность и эффективность. Несмотря на отсутствие ротавирусной вакцинации в рамках национального календаря прививок в России и крайне низкий охват проводимой иммунизацией против ротавирусной инфекции, авторы получают множество вопросов от практикующих педиатров, касающихся частных случаев ротавирусной вакцинации. В представленной статье содержатся полноценные ответы на самые актуальные из них, возникающие в процессе практического использования ротавирусных вакцин.

Rotavirus is recognized as one of the worid’s most common pathogens of acute gastroenteritis among children (up to 5 years of age) and has significant impact on chiidhood morbidity and mortality. The recommended by WHO routine vaccination of infants against rotavirus infection has led to notable reduction in incidence, hospitalization and costs associated with rotavirus infection outcomes in countries that have achieved high vaccination coverage. However, we should be aware of several features of rotavirus vaccines implementation as their safety and efficacy depend on it. Despite the absence of rotavirus vaccination within the National Immunization Schedule in Russian Federation and extremely low coverage of rotavirus preventive vaccination, the authors receive many questions from practicing pediatricians regarding cases of rotavirus vaccination. This article includes complete answers for most relevant of them that arise during practical use of rotavirus vaccines.

ротавирусвакцинациядетипрофилактикаэффективностьrotavirusvaccinationchildrenpreventive careefficacyСтатья подготовлена при поддержке компании ООО ФАРМ ЭЙД ЛТД.The article has been prepared with the support of Pharm Aid LLC.ReferencesWang J, Zhang H, Zhang H, Fang H. Public health impact and costeffectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022;18(7):2090162. https://doi.org/10.1080/21645515.2022.2090162Wang J, Zhang H, Zhang H, Fang H. Public health impact and costeffectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022;18(7):2090162. https://doi.org/10.1080/21645515.2022.2090162WHO. Rotavirus. In: World Health Organization: Official website. Available online: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccines-quality/rotavirus. Accessed on November 15, 2024.WHO. Rotavirus. In: World Health Organization: Official website. Available online: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccines-quality/rotavirus. Accessed on November 15, 2024.Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA Pediatr. 2018;172(10):958–965. https://doi.org/10.1001/jamapediatrics.2018.1960Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA Pediatr. 2018;172(10):958–965. https://doi.org/10.1001/jamapediatrics.2018.1960Clark A, Black R, Tate J, et al. Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements. PLoS One. 2017;12(9):e0183392. https://doi.org/10.1371/journal.pone.0183392Clark A, Black R, Tate J, et al. Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements. PLoS One. 2017;12(9):e0183392. https://doi.org/10.1371/journal.pone.0183392LeClair СЕ, McConnell КА. Rotavirus. [Updated 2023 Jan 2]. In: StatPearls [lnternet]. Treasure lsland (FL): StatPearls Pubishing; 2023.LeClair СЕ, McConnell КА. Rotavirus. [Updated 2023 Jan 2]. In: StatPearls [lnternet]. Treasure lsland (FL): StatPearls Pubishing; 2023.Skansberg A, Sauer M, Tan M, et al. Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Hum Vaccin Immunother. 2021;17(4):1223–1234. https://doi.org/10.1080/21645515.2020.1804245Skansberg A, Sauer M, Tan M, et al. Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Hum Vaccin Immunother. 2021;17(4):1223–1234. https://doi.org/10.1080/21645515.2020.1804245О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2023 году: государственный доклад. — М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека; 2024. — 364 с.O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2023 godu: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Behavior; 364 p. (In Russ).Bencina G, Costantino C, Mameli C, et al. Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review. Expert Rev Vaccines. 2022;21(8):1121–1136. https://doi.org/10.1080/14760584.2022.2075851Bencina G, Costantino C, Mameli C, et al. Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review. Expert Rev Vaccines. 2022;21(8):1121–1136. https://doi.org/10.1080/14760584.2022.2075851Agoti CN, Curran MD, Murunga N, et al. Differences in epidemiology of enteropathogens in children preand post-rotavirus vaccine introduction in Kilifi, coastal Kenya. Gut Pathog. 2022:14:32. https://doi.org/10.1186/sl3099-022-00506-zAgoti CN, Curran MD, Murunga N, et al. Differences in epidemiology of enteropathogens in children preand post-rotavirus vaccine introduction in Kilifi, coastal Kenya. Gut Pathog. 2022:14:32. https://doi.org/10.1186/sl3099-022-00506-zRotavirus vaccines: WHO position paper — July 2021. Weekly Epidemiological Record. 2021:96(28):301-219. Available online: https://iris.who.int/bitstream/handle/10665/342905/WER9628-301-319-eng-fre.pdf?sequence=l. Accessed on November 16,2024.Rotavirus vaccines: WHO position paper — July 2021. Weekly Epidemiological Record. 2021:96(28):301-219. Available online: https://iris.who.int/bitstream/handle/10665/342905/WER9628-301-319-eng-fre.pdf?sequence=l. Accessed on November 16,2024.Vaccine Data Explorer: RotavirusVaccine(Rota). In: VIEW-hub by IVAC. Available online: https://view-hub.org/vaccine/rota. Accessed on November 16, 2024.Vaccine Data Explorer: Rotavirus Vaccine (Rota). In: VIEW-hub by IVAC. Available online: https://view-hub.org/vaccine/rota. Accessed on November 16, 2024.Ротавирусная инфекция: руководство для врачей / под ред. А.А. Баранова, Л.С. Намазовой-Барановой; Союз педиатров России. — 3-е изд., испр. и доп. — Москва: ПедиатрЪ; 2023. — 56 с.Rotavirusnaya infektsiya: А guide for doctors. Baranov AA, Namazova-Baranova LS, eds; Union of Pediatricians of Russia. 3rd edn., rev. and add. Moscow: Pediatr; 2023. 56 p. (In Russ).Коровкин A.C., Игнатьев Г.М. Результаты и перспективы вакцинопрофилактики ротавирусной инфекции в Российской Федерации // БИОпрепараты. Профилактика, диагностика, лечение. — 2023. — Т. 23. — № 4. — С. 499-512. — https://doi.org/10.30895/2221-996X-2023-23-4-499-512Korovkin AS, Ignatyev GM. Results and prospects of rotavirus immunisation in the Russian Federation. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(4):499-512. (In Russ), https://doi.org/10.30895/2221-996X-2023-23-4-499-512Kulkami PS, Desai S, Tewari T, etal. Arandomized Phase III clinical trial to assess the efficacy of a bovine-human reassortantpentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228-6237. https://doi.org/10.1016/J.vaccine.2017.09.014Kulkami PS, Desai S, Tewari T, etal. Arandomized Phase III clinical trial to assess the efficacy of a bovine-human reassortantpentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228-6237. https://doi.org/10.1016/J.vaccine.2017.09.014PoTa-V-Эйд: инструкция no применению. Регистрационное удостоверение № ЛП-23514. Дата регистрации: 24.10.2024 // Реестр ОХЛП и ЛВ ЕАЭС https://lk.regmed.ru/Register/EAEU_SmPC Ссылка активна на 06.12.2024PRota-V-Eid: drug label. Registration certificate No. ЛП-23514. Registration date: June 21, 2021. In: State Register of Medicines: Official website. (In Russ)]Jain S, Haydel MJ. Child Intussusception. 2023Apr 10. In: StatPearIs [Internet]. Treasure Island (FL): StatPearIs Publishing; 2023.Jain S, Haydel MJ. Child Intussusception. 2023Apr 10. In: StatPearIs [Internet]. Treasure Island (FL): StatPearIs Publishing; 2023.Burnett E, Parashar U, Tate J. Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Paediatr Drugs. 2018;20(3):223-233. https://doi.org/10.1007/s40272-018-0283-Burnett E, Parashar U, Tate J. Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Paediatr Drugs. 2018;20(3):223-233. https://doi.org/10.1007/s40272-018-0283-Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and effieaey of an attenuated vaeeine against severe rotavirus gastroenteritis. N EngIJ Med. 2006;354(l):ll-22. https://doi.org/10.1056/NEJMoa052434Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and effieaey of an attenuated vaeeine against severe rotavirus gastroenteritis. N EngIJ Med. 2006;354(l):ll-22. https://doi.org/10.1056/NEJMoa052434Vesikari T, Matson DO, Dennehy R et al. Safety and effieaey of a pentavalent human-bovine (WC3) reassortant rotavirus vaeeine. N Engl J Med. 2006;354(l):23-33. https://doi.org/10.1056/NEJMoa052664Vesikari T, Matson DO, Dennehy R et al. Safety and effieaey of a pentavalent human-bovine (WC3) reassortant rotavirus vaeeine. N Engl J Med. 2006;354(l):23-33. https://doi.org/10.1056/NEJMoa052664Patel MM, Haber R Baggs J, etal. Intussuseeption and rotavirus vaeeination: a review of the available evidenee. Expert Rev Vaccines. 2009;8(11):1555-1564. https://doi.org/10.1586/erv.09.106Patel MM, Haber R Baggs J, etal. Intussuseeption and rotavirus vaeeination: a review of the available evidenee. Expert Rev Vaccines. 2009;8(11):1555-1564. https://doi.org/10.1586/erv.09.106Kim KY, Kim DS. Relationship between Pentavalent Rotavirus Vaeeine and lntussuseeption: A Retrospeetive Study at a Single Center in Korea. Yonsel Med J. 2017;58(3):631-636. https://doi.org/10.3349/ymj.2017.58.3.631Kim KY, Kim DS. Relationship between Pentavalent Rotavirus Vaeeine and lntussuseeption: A Retrospeetive Study at a Single Center in Korea. Yonsel Med J. 2017;58(3):631-636. https://doi.org/10.3349/ymj.2017.58.3.631Cho HK, Hwang SH, Nam HN, et al. Ineidenee of lntussuseeption before and after the introduetion of rotavirus vaeeine in Korea. PLoS One. 2020;15(8):e0238185. https://doi.org/10.1371/Journal.pone.0238185Cho HK, Hwang SH, Nam HN, et al. Ineidenee of lntussuseeption before and after the introduetion of rotavirus vaeeine in Korea. PLoS One. 2020;15(8):e0238185. https://doi.org/10.1371/Journal.pone.0238185World Health Organization. Weekly Epidemiologieal Reeord, 2009,vol.84,23 [full issue]. WeeklyEpldemloIogIcaIReeord = Relevć epidemlologique hebdomadalre. 2009;84(23):213-236. https://apps.who.int/iris/handle/10665/241346World Health Organization. Weekly Epidemiologieal Reeord, 2009,vol.84,23 [full issue]. Weekly EpldemloIogIcaI Record = Relevć epidemlologique hebdomadalre. 2009;84(23):213-236. https://apps.who.int/iris/handle/10665/241346Rotavirus vaeeines. WHO position paper — January 2013. Wkly Epidemiol Rec. 2013;88(5):49-64.Rotavirus vaeeines. WHO position paper — January 2013. Wkly Epidemiol Rec. 2013;88(5):49-64.РотаТек: инcтрукция no применению. Региcтрационное удоcтоверение № ЛП-001865. Дата региетрации: 01.10.2012 // Государственный реестр лекарственных средств: официальный сайт. Доcтупно no: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=20e71417-2el4-4301-8f0d-86adf899e2e5. Сеылка активна на 16.11.2024.RotaTeq: drug label. Registration certificate No. ЛП-001865. Registration date: October 01, 2012. In: State Register of Medieines: Official website. (In Russ).] Доcтупно no: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=20e71417-2el4-4301-8f0d-86adf899e2e5. Сеылка активна на 16.11.2024.Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.. Lancet Glob Health. 2019;7(ll):el541-el552. https://doi.org/10.1016/S2214-109X(19)30412-7Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.. Lancet Glob Health. 2019;7(ll):el541-el552. https://doi.org/10.1016/S2214-109X(19)30412-7Баранов A.A., Намазова-Баранова Л.C., Беляева И.А. и др. Иммунопрофилактика инфекционных болезней у недоношенных детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 5. — С. 376-389. — https://doi.org/10.15690/pf.vl5i5.1960Baranov AA, Namazova-Baranova ES, Belyaeva IA, et al. Immunoprophylaxis of infectious diseases in premature infants. Pediatricheskaya farmakologiya — Pediatric pharmacolog — Pediatric pharmacology. 2018;15(5):376-389. (In Russ), https://doi.org/10.15690/pf.vl5i5.1960Roue JM, Nowak E, Le Gal G, et al. Impact of rotavirus vaccine on premature infants. Clin Vaccine Immunol. 2014;21(10):1404-1409. https://doi.org/10.1128/CVI.00265-14Roue JM, Nowak E, Le Gal G, et al. Impact of rotavirus vaccine on premature infants. Clin Vaccine Immunol. 2014;21(10):1404-1409. https://doi.org/10.1128/CVI.00265-14Флоринская Е.Б., Кешишян E.C. Вакцинация недоношенных детей // Российский вестник перинатологии и педиатрии. — 2021. — Т. 66. — № 6. — С. 6-16. — https://doi.org/10.21508/1027-4065-2021-66-6-6-16Florinskaya ЕВ, Keshishyan ES. Immunization of preterm infants. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2021;66:(6):6-16. (In Russ), https://doi.org/10.21508/1027-4065-2021-66-6-6-1]Kroger A, Bahta L, Long S, Sanchez R General Best Practice Guidelines for Immunization. Available online: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed on November 16, 2024.Kroger A, Bahta L, Long S, Sanchez R General Best Practice Guidelines for Immunization. Available online: www.cdc.gov/ vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed on November 16, 2024.Cortese MM, Haber R Chapter 19: Rotavirus. In: The Epidemiology and Prevention of Vaccine-Preventable Diseases: Course Textbook. 14th edn. 2021. Available online: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-19-rotavirus.html. Accessed on November 16, 2024.Cortese MM, Haber R Chapter 19: Rotavirus. In: The Epidemiology and Prevention of Vaccine-Preventable Diseases: Course Textbook. 14th edn. 2021. Available online: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-19-rotavirus.html. Accessed on November 16, 2024.Rotavirus vaccines: Canadian Immunization Guide. In: Government in Canada. Available online: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-19-rotavirus-vaccine.html#p4cl8a5. Accessed on November 16, 2024.Rotavirus vaccines: Canadian Immunization Guide. In: Government in Canada. Available online: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-19-rotavirus-vaccine.html#p4cl8a5. Accessed on November 16, 2024.Rotavirus. In: Immunisation Handbook-2024. Version 6. Available online: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/20-rotavirus. Accessed on November 16, 2024.Rotavirus. In: Immunisation Handbook-2024. Version 6. Available online: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/20-rotavirus. Accessed on November 16, 2024.Vaccination for preterm infants. Rotavirus vaccine, In: The Australian Immunisation Handbook. Available online: https://immunisationhandbook.health.gov.au/contents/vaccination-forspecial-risk-groups/vaccination-for-preterm-infants#rotavirusvaccine Accessed on November 16, 2024.Vaccination for preterm infants. Rotavirus vaccine, In: The Australian Immunisation Handbook. Available online: https://immunisationhandbook.health.gov.au/contents/vaccination-forspecial-risk-groups/vaccination-for-preterm-infants#rotavirusvaccine Accessed on November 16, 2024.Rotaviren (RV). in: Epldemlologlsches Bulletin. 2023;(4):25. Avaiiabie oniine: https://www.rki.de/DE/Content/infekt/EpidBuii/Archiv/2023/Ausgaben/04_23.pdf?biob=pubiicationFiie. Accessed on November 16, 2024.Rotaviren (RV). in: Epldemlologlsches Bulletin. 2023;(4):25. Avaiiabie oniine: https://www.rki.de/DE/Content/infekt/EpidBuii/Archiv/2023/Ausgaben/04_23.pdf?biob=pubiicationFiie. Accessed on November 16, 2024.Vaccination de L'enfant & de L'adolescent. Vaccination du prćmaturć. Revision 2013. Avaiiabie oniine: https://www.heaith.beigium.be/sites/defauit/fiies/upioads/fieids/fpsheaith_theme_fiie/19090255/Vaccination%20du%20pr%C3%A9matur%C3%A9%20%20enfants%20et%20adoiescents%20-%20r%C3%A9vision%202013.pdf. Accessed on November 16, 2024.Vaccination de L'enfant & de L'adolescent. Vaccination du prćmaturć. Revision 2013. Avaiiabie oniine: https://www.heaith.beigium.be/sites/defauit/fiies/upioads/fieids/fpsheaith_theme_fiie/19090255/Vaccination%20du%20pr%C3%A9matur%C3%A9%20-%20enfants%20et%20adoiescents%20-%20r%C3%A9vision%202013.pdf. Accessed on November 16, 2024.Generai immunization procedures, in: NIAC immunization Guidelines. Royai Coiiege of Physicians of ireiand. Avaiiabie oniine: https://www.hse.ie/eng/heaith/immunisation/hcpinfo/iatentrant.pdf. Accessed on November 16, 2024.Generai immunization procedures, in: NIAC immunization Guidelines. Royai Coiiege of Physicians of ireiand. Avaiiabie oniine: https://www.hse.ie/eng/heaith/immunisation/hcpinfo/iatentrant.pdf. Accessed on November 16, 2024.Иммунопрофилактика инфекционных болезней у недоношенных детей: методические рекомендации / под ред. А.А. Баранова, Л.С. Намазовой-Барановой, И.А. Беляевой и др. — M.: ПедиатрЪ; 2019. — 51 с.Immunoprofllaktlka Infektslonnykh boleznel и nedonoshennykh deter. Ciinicai guideiines. Baranov AA, Namazova-Baranova LS, Beiyaeva ІА, et ai., eds. Moscow: Pediatr; 2019. 52 p. (In Russ)]Hofstetter AM, Lacombe K, Klein EJ, et al. Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Pediatrics. 2018:141(l):e20171110. https://doi.org/10.1542/peds.2017-1110Hofstetter AM, Lacombe K, Klein EJ, et al. Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Pediatrics. 2018:141(l):e20171110. https://doi.org/10.1542/peds.2017-1110Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin. 2011;7(5):563-568. https://doi.org/10.4161/ hv.7.5.15406Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin. 2011;7(5):563-568. https://doi.org/10.4161/ hv.7.5.15406Grimwood K, Lambert SB, Milne RJ. Rotavirus Infections and Vaccines. Pediatr Drugs. 2010;12(4):235-256. https://doi.org/10.2165/11537200-000000000-00000Grimwood K, Lambert SB, Milne RJ. Rotavirus Infections and Vaccines. Pediatr Drugs. 2010;12(4):235-256. https://doi.org/10.2165/11537200-000000000-00000Взаимозаменяемые лекарственные препараты (п. 4 ч. 4 ст. 3 Федерального закона от 27.12.2019 № 475-ФЗ, п. 8 Постановления Правительства от 05.09.2020 № 1360). Доступно no: https://grls.rosminzdrav.ru/Forum/Files/243339/Perechen%20VZ%20(25.05.2022).xls. Ссылка активна на 15.11.2024.Interchangeabie medicinai products (clause 4, part 4, article 3 of the Federal Law of 27.12.2019 No. 475-ФЗ, clause 8 of the Government Resolution of 05.09.2020 No. 1360) (In Russ).] Доступно no: https://grls.rosminzdrav.ru/Forum/Files/243339/Perechen%20VZ%20(25.05.2022).xls. Ссылка активна на 15.11.2024.Clark A, van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.. Lancet infect Dis. 2019;19(7):717-727. https://doi.org/10.1016/S1473-3099(19)30126-4Clark A, van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.. Lancet infect Dis. 2019;19(7):717-727. https://doi.org/10.1016/S1473-3099(19)30126-4Vashishtha VM, Kumar R The durability of vaccine-induced protection: an overview. Expert Rev Vaccines. 2024;23(l):389-408. https://doi.org/10.1080/14760584.2024.2331065Vashishtha VM, Kumar R The durability of vaccine-induced protection: an overview. Expert Rev Vaccines. 2024;23(l):389-408. https://doi.org/10.1080/14760584.2024.2331065Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 effieaey sustained duringthe third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552-4557. https://doi.org/10.1016/J.vaccine.2012.03.030Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 effieaey sustained duringthe third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552-4557. https://doi.org/10.1016/J.vaccine.2012.03.030Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish extension study. Eur J Pediatr. 2010;169(11):1379-1386. https://doi.org/10.1007/s00431-010-1242-3Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish extension study. Eur J Pediatr. 2010;169(11):1379-1386. https://doi.org/10.1007/s00431-010-1242-3Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC infect Dis. 2013:13:112. https://doi.org/10.1186/1471-2334-13-112Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC infect Dis. 2013:13:112. https://doi.org/10.1186/1471-2334-13-112Maguire JE, Glasgow K, Glass K, et al. Rotavirus Epidemiolog and Monovalent Rotavirus Vaccine Effectiveness in Australia: 2010-2017. Pediatrics. 2019;144(4):e20191024. https://doi.org/10.1542/peds.2019-1024Maguire JE, Glasgow K, Glass K, et al. Rotavirus Epidemiolog and Monovalent Rotavirus Vaccine Effectiveness in Australia: 2010-2017. Pediatrics. 2019;144(4):e20191024. https://doi.org/10.1542/peds.2019-1024Huang YC, Wu FT, Huang YC, et al. Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiw/an children. Vaccine. 2020;38(41):6435-6441. https://doi.org/10.1016/j.vaccine.2020.07.067Huang YC, Wu FT, Huang YC, et al. Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiw/an children. Vaccine. 2020;38(41):6435-6441. https://doi.org/10.1016/j.vaccine.2020.07.067Pereira R Vetter V, Standaert B, Benninghoff B. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert Rev Vaccines. 2020;19(8):755-769. https://doi.org/10.1080/14760584.2020.1800459Pereira R Vetter V, Standaert B, Benninghoff B. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert Rev Vaccines. 2020;19(8):755-769. https://doi.org/10.1080/14760584.2020.1800459Middleton BF, Danchin M, Fathima P, et al. Review/ of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006-2021. Vaccine. 2023;41(3):636-648. https://doi.0rg/lO.lOl6/J.vaccine.2022.12.008Middleton BF, Danchin M, Fathima P, et al. Review/ of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006-2021. Vaccine. 2023;41(3):636-648. https://doi.0rg/lO.lOl6/J.vaccine.2022.12.008

The authors declare that there are no conflicts of interest present.